APGE
NASDAQApogee Therapeutics Inc.
$85.63-2.61 (-2.96%)
News25/Ratings12
Price$85.63-0.95 (-1.10%)
01:30 PM07:45 PM
News · 26 weeks80-59%
2025-10-262026-04-19
Mix4190d
- Insider12(29%)
- SEC Filings12(29%)
- Other11(27%)
- Offering3(7%)
- Earnings2(5%)
- Analyst1(2%)
Latest news
25 items- SECSEC Form DEFA14A filed by Apogee Therapeutics Inc.DEFA14A - Apogee Therapeutics, Inc. (0001974640) (Filer)
- SECSEC Form DEF 14A filed by Apogee Therapeutics Inc.DEF 14A - Apogee Therapeutics, Inc. (0001974640) (Filer)
- SECApogee Therapeutics Inc. filed SEC Form 8-K: Leadership Update8-K - Apogee Therapeutics, Inc. (0001974640) (Filer)
- INSIDERSEC Form 4 filed by Henderson Michael Thomas4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
- INSIDERSEC Form 4 filed by Henderson Jane4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
- INSIDERSEC Form 4 filed by Henderson Michael Thomas4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Apogee Therapeutics Inc.SCHEDULE 13G/A - Apogee Therapeutics, Inc. (0001974640) (Subject)
- INSIDERSEC Form 4 filed by Dambkowski Carl4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
- INSIDERSEC Form 4 filed by Henderson Jane4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
- INSIDERSEC Form 4 filed by Henderson Jane4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Apogee Therapeutics Inc.SCHEDULE 13D/A - Apogee Therapeutics, Inc. (0001974640) (Subject)
- PRApogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $403 MillionSAN FRANCISCO and BOSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced the closing of its previously announced underwritten public offering of 5,750,000 shares of its common stock, including the full exercise of the underwriters' option to purchase up to 750,000 additional shares, at a public offering price per share of $70.00. The aggregate gross proceeds to Apogee from the offering were approximately $403 million before deducting underwriting discounts and commissi
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Apogee Therapeutics Inc.SCHEDULE 13G/A - Apogee Therapeutics, Inc. (0001974640) (Subject)
- SECSEC Form 8-K filed by Apogee Therapeutics Inc.8-K - Apogee Therapeutics, Inc. (0001974640) (Filer)
- SECSEC Form 424B5 filed by Apogee Therapeutics Inc.424B5 - Apogee Therapeutics, Inc. (0001974640) (Filer)
- SECSEC Form 144 filed by Apogee Therapeutics Inc.144 - Apogee Therapeutics, Inc. (0001974640) (Subject)
- PRApogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public OfferingSAN FRANCISCO and BOSTON, March 24, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced the pricing of its previously announced underwritten public offering of 5,000,000 shares of its common stock at a public offering price per share of $70.00. The aggregate gross proceeds to Apogee from the offering are expected to be approximately $350 million before deducting underwriting discounts and commissions and other offering expenses payable by Apogee. The offering is expected to close on
- SECSEC Form 424B5 filed by Apogee Therapeutics Inc.424B5 - Apogee Therapeutics, Inc. (0001974640) (Filer)
- PRApogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public OfferingSAN FRANCISCO and BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced that it has commenced an underwritten public offering of $300 million of shares of its common stock. In addition, Apogee expects to grant the underwriters a 30-day option to purchase up to an additional $45 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. The proposed public offering is subject to market and other conditions, and ther
- SECApogee Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events8-K - Apogee Therapeutics, Inc. (0001974640) (Filer)
- PRApogee Therapeutics Announces Positive Phase 2 Part A 52-Week Data of Zumilokibart (APG777), Demonstrating Maintenance and Deepening of Responses with Every 3- and 6-Month Dosing in Moderate-to-Severe Atopic DermatitisAPEX Part A data demonstrated durable maintenance of response at 52-weeks for every 3- and 6-months dosing, respectively, including:- 75% and 85% patients maintained EASI-75- 86% and 78% patients maintained vIGA 0/1Deepening of response was observed across all lesional and itch endpoints with both every 3- and 6- month dosing among the full population of patients initially randomized to zumilokibart Well tolerated across both dosing regimens, with safety profile generally in line with other agents in class APEX Part B 16-week induction expected to readout 2Q 2026, supporting expected initiation of Phase 3 zumilokibart trials in moderate-to-severe atopic dermatitis starting in 2H 2026 Dat
- PRApogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026SAN FRANCISCO and BOSTON, March 22, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced it will report Part A 52-week data from the Phase 2 APEX trial of zumilokibart on Monday, March 23, 2026. Following the announcement, the company will host a conference call and webcast at 8:00 a.m. ET to discuss the results. Webcast DetailsApogee Therapeutics' live webcast of the Phase 2 APEX Part A results will begin on Monday, March 23rd at 8:00 a.m. ET. The live webcast can be accessed via this l
- ANALYSTTruist initiated coverage on Apogee Therapeutics with a new price targetTruist initiated coverage of Apogee Therapeutics with a rating of Hold and set a new price target of $83.00
- INSIDERChief Executive Officer Henderson Michael Thomas sold $1,495,605 worth of shares (20,000 units at $74.78), decreasing direct ownership by 2% to 1,152,987 units (SEC Form 4)4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)
- INSIDERChief Medical Officer Dambkowski Carl exercised 4,125 shares at a strike of $22.86 and sold $390,825 worth of shares (5,500 units at $71.06), decreasing direct ownership by 0.65% to 209,773 units (SEC Form 4)4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)